FatiAbGen Co. Ltd., established in Korea in 2020, engineers best in class antibodies, tailored for multiple modalities such as ADCs, bi-specifics, and Car-T, to address difficult targets in oncology and immunology. We focus on the highest unmet need indications.
We have an active collaboration strategy with world-class partners, always with the goal to develop the best products faster and to de-risk programs as much as possible by the time they reach IND.